Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Human T-cell receptors (TCRs) specific for PfPEBS-derived peptides are specialized immune receptors that recognize antigens from the malaria parasite Plasmodium falciparum (Frontiers in Immunology, 2019). PfPEBS (Pre-Erythrocytic and Blood Stage) is a synthetic polypeptide derived from the Pf11.1 antigen, a large protein expressed during both the liver and blood stages of the parasite's life cycle (ClinicalTrials.gov, 2012). These TCRs bind to specific PfPEBS peptide fragments presented by Major Histocompatibility Complex (MHC) molecules, primarily on the surface of infected hepatocytes or antigen-presenting cells (NIH, 2025). This recognition is a critical component of the cellular immune response, leading to the activation of CD4+ and CD8+ T cells, which produce pro-inflammatory cytokines like interferon-gamma to inhibit parasite development (Infection and Immunity, 2010). In the context of drug and vaccine development, these TCRs are targets for monitoring vaccine-induced immunity or for developing adoptive T-cell therapies aimed at providing sterile protection against malaria infection (PLoS ONE, 2015). The interaction between these TCRs and PfPEBS-derived peptides is currently a focus of clinical research, particularly in the evaluation of the PfPEBS-LSP vaccine candidate (Frontiers in Immunology, 2019).
The T-cell receptor recognizes specific peptide fragments derived from the Pf11.1 protein (PfPEBS) when presented by Major Histocompatibility Complex (MHC) molecules on the surface of infected cells or antigen-presenting cells. This binding event triggers a signaling cascade that leads to T-cell activation, proliferation, and the secretion of effector cytokines such as interferon-gamma (IFN-gamma), which contribute to the elimination of Plasmodium falciparum parasites in both the liver and blood stages (Frontiers in Immunology, 2019; NIH, 2025).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Human T-cell receptor specific for Plasmodium falciparum Pre-Erythrocytic and Blood Stage (PfPEBS)-derived peptides.